Vásquez-Awad D

Language: Spanish
References: 27
Page: 47-55
PDF size: 247.16 Kb.

ABSTRACT

After 40 years, combined oral contraceptives have shown an optimal safety profile that allows to indicate them to different age groups. In recent years it has been observed that, along with the contraceptive effect for which they were created, combined oral hormones offer various beneficial effects, gynecological or not, that have been studied carefully. The purpose of this article is to analyze, in the light of the evidence, the beneficial non-contraceptive effects of combined oral hormones in women not interested in planning her family. Combined oral contraceptives have a positive impact on the life of women in reproductive age, not only from a medical point of view, but also in the social, emotional, anthropological, economic and self-esteem fields. The control of fertility has been one of the most notorious advances in the struggle –which belongs to all gynecologists– to achieve gender equality. In addition to the contraceptive effects of combined oral hormones, the gynecological and non-gynecological benefits of these drugs are also recognized.

REFERENCES

1. Huxley A. Brave new world revisited. New York: Harper and Row, 1958:138-139. https://archive.org/stream/Brave_ New_World_Revisited/Brave%20New%20World%20 Revisited%20-%20Huxley%20%281958%29_djvu.txt

2. Peterson HB, et al. The health effects of oral contraceptives: Misperceptions, controversies, and continuing good news. Clin Obstet Gynecol 1989;32:339-355.

3. Panser LA, et al. Type of oral contraceptive in relation to acute, initial episodes of pelvic inflammatory disease. Contraception 1991;43:91-9. https://doi.org/10.1016/0010- 7824(91)90130-8

4. van Hoof MH, et al. The use of oral contraceptives by adolescents for contraception, menstrual cycle problems or acne. Acta Obstet Gynecol Scand 1998;77(9):898-904. https://doi.org/10.1034/j.1600-0412.1998.770905.x

5. Sundell G, et al. Factors influencing the prevalence and severity of dysmenorrhea in young women. Br J Obstet Gynaecol 1990;97:588-594. https://doi. org/10.1111/j.1471-0528.1990.tb02545.x

6. Lanes SF, et al. Oral contraceptive type and functional ovarian cysts. Am J Obstet Gynecol 1992;166:956-961. https://doi.org/10.1016/0002-9378(92)91371-G

7. Ross RK, et al. Risk factors for uterine fibroids: Reduced risk associated with oral contraceptives. BMJ (Clin Res Ed) 1986;293(6543):359-362. https://www.bmj.com/content/ bmj/293/6543/359.full.pdf

8. Chiaffarino F, et al. Use of oral contraceptives and uterine fibroids: results from a case-control study. Br J Obstet Gynecol 1999;106:857-860. https://obgyn.onlinelibrary. wiley.com/doi/epdf/10.1111/j.1471-0528.1999.tb08409.x

9. Cancer and Steroid Hormone Study of the Center for Disease Control and the National Institute of Child Health and Human Development. The reduction in risk of ovarian cancer associated with oral-contraceptive use. N Engl J Med 1987;316:650-655. https://www.nejm.org/doi/ full/10.1056/NEJM198703123161102

10. Hankinson SE, et al. A quantitative assessment of oral contraceptive use and risk of ovarian cancer. Obstet Gynecol 1992;80:708-714.

11. Narod SA, et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 1998;339:424-428.

12. Schlesselman JJ. Risk of endometrial cancer in relation to use of combined ral contraceptives: A practitioner´s guide to meta-analysis. Hum Reprod 1997;12:1851-1863.

13. Sherman ME, et al. Risk factors and hormone levels in patients with serous and endometrioid uterine carcinomas. Mod Pathol 10:963-968,1997.

14. Vessey M, et al. Oral contraceptive use and cancer. Findings in a large cohort study, 1968-2004. Br J Cancer 2006;95:385- 389. https://www.nature.com/articles/6603260

15. Parazzini F, et al. Contraceptive methods and risk of pelvic endometriosis. Contraception 1994;49:47-55

16. Moore J, et al. Modern combined oral contraceptives for pain associated with endometriosis. Cochrane Database Syst Rev 1999;3:3. http://cochranelibrary-wiley.com/ doi/10.1002/14651858.CD001019/full

17. Martínez ME, et al. A prospective study of reproductive factors, oral contraceptive use, and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 1997;6:1-5. http://cebp. aacrjournals.org/content/6/1/1.full-text.pdf

18. Franceschi S, et al. Oral contraceptives and colorectal tumors: A review of epidemiologis studies. Contraception 1998;58:335-343. https://doi.org/10.1016/S0010- 7824(98)00128-0

19. Milman N, et al. Iron status in 268 Danish women aged 18-30 years: Influence of menstruation, contraceptive method, and iron supplementation. Ann Hematol 1998;77(1-2):13-19. https://link.springer.com/article/10.1007/s002770050405

20. Lucky AW, et al. Effectiveness of norgestimate and ethynil estradiol in treating moderates acne vulgaris. J Am Acad Dermatol 1997;37(5 pt 1):746-54. https://doi.org/10.1016/ S0190-9622(97)70112-9

21. Redmond GP, et al. Norgestimate and ethynil estradiol in the treatment of acne vulgaris: A randomized , placebocontrolled trial. Obstet Gynecol 1997;89:615-622. https:// doi.org/10.1016/S0029-7844(97)00059-8

22. Gambacciani M, et al. Longitudinal evaluation of perimenopausal vertebral bone loss: Effects of a low-dose oral contraceptive preparation on bone mineral density and metabolism. Obstet Gynecol 1994;83:392-396.

23. Kleerekoper M, et al. Oral contraceptive use may protect against low bone mass. Henry Ford Hospital Osteopo- rosis Cooperative Research Group. Arch Intern Med 1991;151:1971-1976.

24. Michaelsson K, et al. Oral contraceptive use and risk of hip fracture: A case-control study. Lancet 1999;353(9163):1481-1484. https://doi.org/10.1016/ S0140-6736(98)09044-8

25. Brinton LA, et al. Risk factors for benign breast disease. Am J Epidemiol 1981;113:203-214. https://doi.org/10.1093/ oxfordjournals.aje.a113089

26. Brennan P, et al. Oral contraceptives and rheumatoid arthritis: results from a primary care-based incident casecontrol study. Semin Arthritis Rheum 1997;26:817-823. https://www.semarthritisrheumatism.com/article/S0049- 0172(97)80025-X/pdf

27. Burkman R, et al. Safety concerns and health benefits associated with oral contraception. Am J Obstet Gynecol 2004;190(4)(S1):S5-S22. https://doi.org/10.1016/j. ajog.2004.01.061.